Professor Anthony Gordon is the Chair in Anaesthesia and Critical Care at Imperial College and is a Consultant in Intensive Care Medicine based at St Mary's Hospital.
He received his medical degree from St Bartholomew’s Medical School in 1993 and then undertook his postgraduate medical training across the North Thames regions with an additional year spent at The Royal North Shore Hospital in Sydney, Australia. He was awarded the Fellowship of the Royal College of Anaesthetists in 1999 and returned to Barts to obtain his research doctorate examining genetic susceptibility in sepsis.
Having obtained a dual CCST in Anaesthesia and Intensive Care Medicine he was awarded the Intensive Care Society visiting fellowship in 2005 and spent two years in Vancouver at St Paul’s Hospital, University of British Columbia as a post-doctorate fellow. During this time he also worked as the Director of Medical Development of a university spin-out company developing pharmacogenetic tests for use in the ICU.
Prof Gordon returned to the Imperial AHSC in November 2007, and was a recipient of a Clinician Scientist Fellowship award from the National Institute for Health Research (NIHR) and is currently an NIHR Research Professor investigating Precision Medicine in Sepsis.
His research is focused on clinical trials and translational studies in sepsis. Particularly
- He is the UK Chief Investigator for the international REMAP-CAP platform trial evaluating treatments for COVID-19. This has demonstrated in severe COVID-19, that the IL-6 receptor antagonists, tocilizumab and sarilumab, saves lives and speed up recovery, as do corticosteroids.
- He has been the Chief investigator for two multi-centre trials examining alternatives to catecholamines in septic shock. Early vasopressin use in septic shock and its interaction with corticosteroids (VANISH trial) and also levosimendan for the prevention of organ failure (LeoPARDS trial).
- He leads the "Emergency and Critical Care" therapeutic group within the Imperial Clinical Trials Unit.
- He is a Director of Research for the Intensive Care Society.
- He is Chair of the Experimental Medicine subgroup of the NIHR Critical Care Specialty Group helping to deliver nationwide clinical studies and linking with industry partners.
- He is leads a multidisciplinary group investigating the use of -omic techniques and artificial intelligence to improve care and outcomes in sepsis
et al., 2021, Interleukin-6 receptor antagonists in critically Ill patients with Covid-19, New England Journal of Medicine, Vol:384, ISSN:0028-4793, Pages:1491-1502
Angus DC, Gordon AC, Bauchner H, 2021, Emerging lessons from COVID-19 for the US clinical research enterprise, JAMA - Journal of the American Medical Association, ISSN:0098-7484, Pages:E1-E3
et al., 2020, Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis., Jama, Vol:324, Pages:1330-1341
et al., 2020, Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19, JAMA - Journal of the American Medical Association, Vol:324, ISSN:0098-7484, Pages:1317-1329
et al., 2020, The randomized embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design, Annals of the American Thoracic Society, Vol:17, ISSN:2329-6933, Pages:879-891
et al., 2020, Artificial intelligence vs. clinicians – a systematic review of the design, reporting standards, and claims of deep learning studies in diagnostic medical imaging, British Medical Journal, Vol:368, ISSN:0959-535X
et al., 2019, Transcriptomic signatures in sepsis and a differential response to steroids: from the VANISH randomized trial, American Journal of Respiratory and Critical Care Medicine, Vol:199, ISSN:1073-449X, Pages:980-986
et al., 2018, The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care, Nature Medicine, Vol:24, ISSN:1078-8956, Pages:1716-1720
et al., 2016, Levosimendan for the prevention of acute organ dysfunction in sepsis, New England Journal of Medicine, Vol:375, ISSN:0028-4793, Pages:1638-1648
et al., 2016, Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study, Lancet Respiratory Medicine, Vol:4, ISSN:2213-2619, Pages:259-271
et al., 2008, Vasopressin versus norepinephrine infusion in patients with septic shock, New England Journal of Medicine, Vol:358, ISSN:0028-4793, Pages:877-887